Drugmaker Ionis's Q2 revenue doubles, beats expectations; hikes guidance
Overview
Ionis Q2 2025 revenue doubles yr/yr, beating analyst expectations
Adjusted operating income beats expectations, driven by TRYNGOLZA launch
Co raises 2025 financial guidance, citing improved outlook and performance
Outlook
Ionis raises 2025 revenue guidance to $825-850 mln
Company expects TRYNGOLZA sales of $75-80 mln in 2025
Ionis anticipates sustained growth and positive cash flow
Result Drivers
TRYNGOLZA LAUNCH - Strong revenue growth driven by TRYNGOLZA's successful launch, generating $19 mln in Q2 sales
ROYALTY REVENUE - Increased royalty revenue from products like SPINRAZA and WAINUA contributed to revenue growth
COMMERCIAL INVESTMENTS - Operating expenses rose due to investments in commercializing TRYNGOLZA, donidalorsen, and WAINUA
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Beat | $452 mln | $295.20 mln (19 Analysts) |
Q2 Net Income |
| $124 mln |
|
Q2 Adjusted Operating Income | Beat | $170 mln | -$44.90 mln (12 Analysts) |
Q2 Adjusted Operating Expenses |
| $282 mln |
|
Q2 Operating Expenses |
| $312 mln |
|
Q2 Operating Income |
| $140 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 18 "strong buy" or "buy", 8 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Ionis Pharmaceuticals Inc is $58.00, about 28.5% above its July 29 closing price of $41.48
Press Release: ID:nBwfCpmBa
